Single-Center Study Evaluating the Impact of Age on the Diagnostic Performance of the Sural-to-Ra… (NCT07725120) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Single-Center Study Evaluating the Impact of Age on the Diagnostic Performance of the Sural-to-Radial Sensory Amplitude Ratio in Length-Dependent and Non-Length-Dependent Peripheral Polyneuropathies
France180 participantsStarted 2026-09-01
Plain-language summary
This retrospective single-center observational study will evaluate the impact of age on the diagnostic performance of the sural-to-radial sensory nerve amplitude ratio (SRAR) in patients with length-dependent and non-length-dependent peripheral sensory polyneuropathies. Clinical and electrophysiological data collected during routine care between January 2013 and July 2026 will be analyzed. Diagnostic performance will be assessed using receiver operating characteristic (ROC) curve analysis across predefined age groups to determine whether age-adjusted SRAR thresholds improve the differentiation between the two polyneuropathy phenotypes.
Who can participate
Age range
18 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 18 years or older.
* Diagnosis of peripheral sensory polyneuropathy.
* Classification as length-dependent (LDN) or non-length-dependent (NLDN) based on clinical and electrophysiological findings.
* Available nerve conduction study including sural and radial sensory nerve amplitudes allowing calculation of the SRAR.
* Evaluated at the Peripheral Neuromuscular Rare Disease Reference Center, Nice University Hospital, between January 2013 and July 2026.
Exclusion Criteria:
* Missing or incomplete clinical or electrophysiological data preventing SRAR calculation.
* Unclassifiable neuropathy phenotype.
* Technical factors affecting the reliability of nerve conduction studies.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Diagnostic performance of the sural-to-radial sensory nerve amplitude ratio (SRAR)
Timeframe: Baseline (retrospective analysis of data collected between January 2013 and July 2026